A vs ADBE Stock Comparison

Scores Breakdown

Metric	A	ADBE
📈 Growth	18/30	28/30
💰 Profitability	16/20	18/20
🏦 Financial Health	7/20	14/20
💵 Valuation	9/20	14/20
⚠️ Risk (lower is better)	7/10	6/10
Overall Score	53/100	78/100

Side-by-Side Summaries

A Analysis	ADBE Analysis
📈 Growth & Financial Trajectory Over eight quarters, Revenues rose from about $1.66B to $1.84B, a positive trend, with a mid-2025 dip. Net income fluctuated from $308M–$434M, ending near $339M in 2026 Q2. The sequence shows top-line resilience but earnings volatility, implying improving mix or cost management but not a steady uplift in profitability. 💰 Margins & Cash Flow Gross Margin is generally in the mid-50s percentile, peaking around 63% in 2024 Q2 and typical ~50–55% in other quarters. Operating Margin has run in the high-teens to low-20s percent range on Revenues of ~$1.6–$1.8B. Operating cash flow remains positive across quarters (roughly $0.27–$0.55B), while investing cash flow is negative (capital outlays), and financing cash flow is often negative, reflecting debt/return actions. 🛡️ Balance Sheet & Liquidity Total Assets (~~$11–$13B) exceed Liabilities (~~$4.8–$6B) with Equity frequently negative, signaling balance-sheet rehabilitation needs. Current assets vs current liabilities suggests solid liquidity (working capital positive); long-term debt remains a meaningful load but generally manageable within cash flows. ⚠️ Key Drivers & Risks Drivers: Life sciences capex & instrument upgrades; continued demand for laboratory testing and automation. Risks: Earnings volatility from cyclic lab-spend; structural negative equity raises valuation sensitivity and balance-sheet risk.	📈 Growth & Financial Trajectory Eight quarters show a steady top-line advance from about Revenues of $5.31B to about $6.62B, a roughly 25% gain. Net income remained resilient around $1.7–$1.9B, with modest quarterly swings. The company sustained strong operating margins aided by high gross margin discipline, underscoring durable profitability across periods. 💰 Margins & Cash Flow Gross margin stayed in the high-80s, supporting healthy operating income of roughly $2.0–$2.4B on $5.3–$6.6B in Revenues. Net cash flow from operating activities tended positive around $2–3B per quarter, while investing/financing activities produced meaningful outflows, leading to periodic negative overall cash flow. Cash balances ranged ~$5–8B, with a gradual but modest decline as capital deployment evolved. 🛡️ Balance Sheet & Liquidity Total assets sit near $29–30B with liabilities around $18–18.5B and equity near $11.5B, signaling solid capitalization. The near-term liquidity position shows a tighter profile: current assets ~ $9.0B vs current liabilities ~ $12.0B. Cash reserves provide liquidity, though aggregate cash declined in later quarters due to investing/financing activity. ⚠️ Key Drivers & Risks Drivers: AI-enabled features in Creative Cloud; ongoing subscription growth and enterprise adoption. Risks: Valuation sensitivity to growth trajectory; macro/enterprise spending cycles; competitive pressure in creative software.

A Analysis

ADBE Analysis

📈 Growth & Financial Trajectory

Over eight quarters, Revenues rose from about $1.66B to $1.84B, a positive trend, with a mid-2025 dip. Net income fluctuated from $308M–$434M, ending near $339M in 2026 Q2. The sequence shows top-line resilience but earnings volatility, implying improving mix or cost management but not a steady uplift in profitability.

💰 Margins & Cash Flow

Gross Margin is generally in the mid-50s percentile, peaking around 63% in 2024 Q2 and typical ~50–55% in other quarters.
Operating Margin has run in the high-teens to low-20s percent range on Revenues of ~$1.6–$1.8B.
Operating cash flow remains positive across quarters (roughly $0.27–$0.55B), while investing cash flow is negative (capital outlays), and financing cash flow is often negative, reflecting debt/return actions.

🛡️ Balance Sheet & Liquidity

Total Assets (~~$11–$13B) exceed Liabilities (~~$4.8–$6B) with Equity frequently negative, signaling balance-sheet rehabilitation needs. Current assets vs current liabilities suggests solid liquidity (working capital positive); long-term debt remains a meaningful load but generally manageable within cash flows.

⚠️ Key Drivers & Risks

Drivers: Life sciences capex & instrument upgrades; continued demand for laboratory testing and automation.
Risks: Earnings volatility from cyclic lab-spend; structural negative equity raises valuation sensitivity and balance-sheet risk.

📈 Growth & Financial Trajectory

Eight quarters show a steady top-line advance from about Revenues of $5.31B to about $6.62B, a roughly 25% gain. Net income remained resilient around $1.7–$1.9B, with modest quarterly swings. The company sustained strong operating margins aided by high gross margin discipline, underscoring durable profitability across periods.

💰 Margins & Cash Flow

Gross margin stayed in the high-80s, supporting healthy operating income of roughly $2.0–$2.4B on $5.3–$6.6B in Revenues. Net cash flow from operating activities tended positive around $2–3B per quarter, while investing/financing activities produced meaningful outflows, leading to periodic negative overall cash flow. Cash balances ranged ~$5–8B, with a gradual but modest decline as capital deployment evolved.

🛡️ Balance Sheet & Liquidity

Total assets sit near $29–30B with liabilities around $18–18.5B and equity near $11.5B, signaling solid capitalization. The near-term liquidity position shows a tighter profile: current assets ~ $9.0B vs current liabilities ~ $12.0B. Cash reserves provide liquidity, though aggregate cash declined in later quarters due to investing/financing activity.

⚠️ Key Drivers & Risks

Drivers: AI-enabled features in Creative Cloud; ongoing subscription growth and enterprise adoption.
Risks: Valuation sensitivity to growth trajectory; macro/enterprise spending cycles; competitive pressure in creative software.

Similar Companies

AMAT Score: 80 AME Score: 81 ANET Score: 84 GOOGL Score: 78 TMO Score: 75 WAT Score: 78

Top Rated Companies

View Top 20 →

MU "MICRON TECHNOLOGY INC"

AVGO "Broadcom Inc."

KMI "KINDER MORGAN, INC."

MNST "Monster Beverage Corp"

NEM "NEWMONT Corp /DE/"